Osteoarthritis treatment and device
A method for treating arthritis of a joint includes identifying a bone lesion in a bone adjacent to the joint; and implanting in the bone a reinforcing member in or adjacent to the bone lesion. A kit for conducting the method includes: (a) at least one reinforcing member having a proximal face adapted to face the joint, a distal face adapted to face away from the joint, and a wedge-shaped edge adapted to pierce bone, wherein the at least one reinforcing member is planar and sterile; and (b) a container adapted to maintain the at least one reinforcing member sterile. Another kit includes: (a) a sterile fluid; (b) a syringe for injecting the fluid into a bone; (c) a curing agent adapted to cure the fluid to polymerize and/or cross-link; and (d) a container adapted to maintain the sterility of contents of the container.
1. A method of injecting an injectable fluid material into a targeted treatment area in a subchondral region of a first bone adjacent a knee joint, the method comprising:
identifying a bone marrow lesion that is less than 10 cm from a knee joint through use of magnetic resonance imaging (MRI) of the knee joint, the bone marrow lesion occurring in a subchondral region of a first bone adjacent the knee joint, the subchondral region of the first bone occurring under an articular surface of the first bone;
creating, in the first bone that contains the bone marrow lesion in the subchondral region, a subchondral injection path to a targeted treatment area for injecting an injectable fluid material into the targeted treatment area, wherein the targeted treatment area includes an area in the subchondral region where the bone marrow lesion was identified and/or an area in the subchondral region that is up to 1 cm from where the bone marrow lesion was identified, and wherein said creating preserves an existing condition of the overlying articular cartilage of the first bone adjacent the knee joint and is conducted without further creating a void inside the first bone in or adjacent to the targeted treatment area; and
injecting an injectable fluid material into the targeted treatment area via the subchondral injection path, wherein the injectable fluid material is left in the targeted treatment area without also delivering and leaving a solid structural implant in the targeted treatment area in addition to the injectable fluid material, wherein the injectable fluid material includes an osteogenic, osteoconductive and/or osteoinductive material.
2. The method of claim 1 , wherein the injectable fluid material includes bone marrow.
3. The method of claim 1 , wherein said identifying the bone marrow lesion through use of magnetic resonance imaging (MRI) of the knee joint is viewing the bone marrow lesion on an MRI of the knee joint.
4. The method of claim 1 , wherein the targeted treatment area includes an area in the subchondral region where the bone marrow lesion was identified.
5. The method of claim 1 , wherein the targeted treatment area includes an area in the subchondral region that is up to 1 cm from where the bone marrow lesion was identified.
6. The method of claim 1 , wherein the target treatment area includes an area in the subchondral region where the bone marrow lesion was identified and an area in the subchondral region that is up to 1 cm from where the bone marrow lesion was identified.
7. The method of claim 1 , wherein the bone marrow lesion is less than 5 cm from the knee joint.
8. The method of claim 1 , wherein the bone marrow lesion is less than 1 cm from the knee joint.
9. The method of claim 1 , wherein said injectable fluid material includes a calcium phosphate.
10. The method of claim 1 , wherein the bone marrow lesion is in a proximal tibia.
11. The method of claim 1 , wherein the bone marrow lesion is in a distal femur.
12. A method of injecting an injectable fluid material into a targeted treatment area in a subchondral region of a first bone adjacent a knee joint, the method comprising:
identifying a bone marrow lesion that is less than 10 cm from a knee joint through use of magnetic resonance imaging (MRI) of the knee joint so as to establish an identified bone marrow lesion, the identified bone marrow lesion occurring in a subchondral region of a first bone adjacent the knee joint, the subchondral region of the first bone occurring under an articular surface of the first bone;
targeting a treatment area in the subchondral region of the first bone so as to establish a targeted treatment area for receiving treatment, wherein the targeted treatment area is in the subchondral region in and/or adjacent to the identified bone marrow lesion,
creating, in the first bone that contains the identified bone marrow lesion in the subchondral region, a subchondral injection path to the targeted treatment area for injecting an injectable fluid material into the targeted treatment area, wherein said creating preserves an existing condition of the overlying articular cartilage of the first bone adjacent the knee joint and is conducted without further creating a void inside the first bone in or adjacent to the targeted treatment area; and
injecting an injectable fluid material into the targeted treatment area via the subchondral injection path, wherein the injectable fluid material is left in the targeted treatment area without also delivering and leaving a solid structural implant in the targeted treatment area in addition to the injectable fluid material, and wherein the injectable fluid material includes an osteogenic, osteoconductive and/or osteoinductive material.
13. The method of claim 12 , wherein the targeted treatment area includes an area in the identified bone marrow lesion and/or an area that is up to 1 cm from the identified bone marrow lesion.
14. The method of claim 12 , wherein the targeted treatment area includes an area in the identified bone marrow lesion and/or an area that is up to 5 cm from the identified bone marrow lesion.
15. The method of claim 14 , wherein the targeted treatment area includes an area in the identified bone marrow lesion and an area that is up to 5 cm from the identified bone marrow lesion.
16. The method of claim 14 , wherein the targeted treatment area includes an area in the identified bone marrow lesion.
17. The method of claim 14 , wherein the targeted treatment area includes an area that is up to 5 cm from the identified bone marrow lesion.
18. The method of claim 12 , wherein the injectable fluid material includes bone marrow.
19. The method of claim 12 , wherein the identified bone marrow lesion is less than 5 cm from the knee joint.
20. The method of claim 12 , wherein the identified bone marrow lesion is less than 1 cm from the knee joint.
21. The method of claim 12 , wherein said injectable fluid material includes a calcium phosphate.
22. The method of claim 12 , wherein the identified bone marrow lesion is in a proximal tibia.
23. The method of claim 12 , wherein the identified bone marrow lesion is in a distal femur.